WuXi AppTec IPO Valuation:Ā Not Much Money Left on the Table
WuXi AppTec Co. Ltd. (WUXI HK)Ā is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....
792 Views
Wuxi Apptec čÆęåŗ·å¾· IPO: Welcome to the A/H Universe
WuXi Apptec is set to be the newest A/H pair with its upcoming HK listing that is set to raise USD 1 billion. The A-share (603289 CH) recorded 15...
1k Views
New Stem Cell Treatment for Parkinsons Positive for Catalent and Eisai
A pioneering new stem cell treatment with the 'potential to cure Parkinson's disease' has been crafted by researchers. In trials on laboratory...
280 Views
WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China
WuXi Biologics (2269 HK) is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares. Ā Proceeds will be used...
1k Views
WuXi Biologics: Pass on This Valuation
The company's underwriters have announced a price range of HK$18.60 - HK$20.60 which implies a marketĀ cap of US$2.7-3.0 billion. We recommend...
987 Views